Topical Micronutrient Products by Darlene McCord
PART IV

David E. Davenport, M.D., FACR
Darlene McCord, Ph.D., FAPWCA
Brenda Bull R.T. (R)(T)

Quality of Life Results

Twenty-six members of the Remedy treatment group completed vDLQI questionnaires during five weeks of radiotherapy. Patients using the Remedy products reported lower impairment scores and higher rates of compliance, resulting in greater vDLQI values. According to patient reviews, QL was maintained due to the products’ effectiveness against pain and pruritus, and decreased "greasiness" and "stickiness". In particular, patients reported low impairment scores for vDLQI-Question #1 throughout the entire treatment period. Question #1 asked patients to determine the degree to which their skin had been "itchy, sore, painful and/or stinging" during the previous week.

Patients being treated with Remedy products maintained an average Question #1-impairment score of 0.53. Furthermore, at the end of Week 5 when radiotherapy damage had the most time to accumulate, the mean impairment score was below 1.0. A score of 0.0 signifying impairment that is "Not at all" recognized, and a score of 1.0 indicating impairment that is recognized "A little". In fact, over 46% of the patients reported either no change in impairment or a lesser degree of impairment from Week 1 to Week 5.